Overview

Phase ll Study of HEC585 in Patients With PF-ILD

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with progressive-fibrosing interstitial lung diseases.

Phase:

Phase 2

Details

Lead Sponsor:

Sunshine Lake Pharma Co., Ltd.